NICE AMR related activities

‘OUTPUTS’
- NG15 Antimicrobial Stewardship
- Syndrome Specific Short Guidelines
- New AM Evidence Summaries
- Transformational AM Guidance (TA)
- AMR Diagnostics
- MedTech Briefings

‘INTERACTIONS’
- NHSE/NICE Diagnostics Liaison Group
- NHSE AMR Diagnostics Subgroup
- ESPAUR
- PHE
- DH
- Medicines Optimisation Initiatives
The Diagnostics
Clinical and Cost Effectiveness Challenge

Complexity and variation in diagnostic and care pathways
Alternates i.e. more than 1 technology posing the same value proposition
Benefits typically result indirectly i.e. from treatments rather than directly from diagnostic procedures
Real world implementation uncertainty
Rapid product evolution i.e. short product life cycles
End to end clinical studies following patients from diagnosis through care to outcomes rarely available
Lower level of resources available in diagnostic ‘sector’

‘Accommodated’ by NICE DAP Methods and Processes

But what about capturing the ‘externalities/benefits’ relating to AM stewardship?
AMR Diagnostics related MedTech Briefings

**MedTech Briefings=Advice**

- **Product Description**
- **Place in Pathway**
- **Evidence Summary**

- **Alere Afinion CRP for C-reactive protein testing in primary care**
- **QuikRead go for C-reactive protein testing in primary care**
- **Xpert GBS test for the intrapartum detection of group B streptococcus**
- **Xpert Carba-R to identify people carrying carbapenemase-producing organisms**
- **BD MAX Enteric Bacterial Panel for identifying pathogens in contagious gastroenteritis**
- **AdenoPlus point-of-care test for diagnosing adenoviral conjunctivitis**

‘Multi-MIB’ format being finalised with AMR Diagnostics in mind

https://www.nice.org.uk/guidance/published?type=mib